Is Sunshine Biopharma Stock a Good Investment?
Sunshine Biopharma Investment Advice | SBFMW |
- Examine Sunshine Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sunshine Biopharma's leadership team and their track record. Good management can help Sunshine Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Sunshine Biopharma's business and its evolving consumer preferences.
- Compare Sunshine Biopharma's performance and market position to its competitors. Analyze how Sunshine Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Sunshine Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sunshine Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sunshine Biopharma Warrant stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sunshine Biopharma Warrant is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Sunshine Biopharma Stock
Researching Sunshine Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 2.21. Sunshine Biopharma had not issued any dividends in recent years.
To determine if Sunshine Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sunshine Biopharma's research are outlined below:
| Sunshine Biopharma is way too risky over 90 days horizon | |
| Sunshine Biopharma has some characteristics of a very speculative penny stock | |
| Sunshine Biopharma appears to be risky and price may revert if volatility continues | |
| Sunshine Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 10.14 M. | |
| Sunshine Biopharma Warrant has accumulated about 40.56 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sunshine Biopharma has a poor financial position based on the latest SEC disclosures |
Sunshine Biopharma Quarterly Accounts Payable |
|
Sunshine Biopharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.16) | |
| Return On Capital Employed | (0.20) | (0.19) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.24) | (0.23) |
Determining Sunshine Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Sunshine Biopharma is a good buy. For example, gross profit margin measures Sunshine Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sunshine Biopharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Sunshine Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sunshine Biopharma Warrant. Check Sunshine Biopharma's Beneish M Score to see the likelihood of Sunshine Biopharma's management manipulating its earnings.
Evaluate Sunshine Biopharma's management efficiency
The company has return on total asset (ROA) of (0.1075) % which means that it has lost $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1798) %, meaning that it generated substantial loss on money invested by shareholders. Sunshine Biopharma's management efficiency ratios could be used to measure how well Sunshine Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.16 in 2025. Return On Capital Employed is likely to climb to -0.19 in 2025. At this time, Sunshine Biopharma's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 30.1 M in 2025, despite the fact that Non Currrent Assets Other are likely to grow to (1.7 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.6 K | 1.6 K | |
| Tangible Book Value Per Share | 1.5 K | 1.5 K | |
| Enterprise Value Over EBITDA | 2.12 | 2.23 | |
| Price Book Value Ratio | 0.36 | 0.34 | |
| Enterprise Value Multiple | 2.12 | 2.23 | |
| Price Fair Value | 0.36 | 0.34 |
Sunshine Biopharma has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta (1.48) |
Basic technical analysis of Sunshine Stock
As of the 27th of March, Sunshine Biopharma has the Semi Deviation of 16.25, coefficient of variation of 843.26, and Risk Adjusted Performance of 0.11. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sunshine Biopharma, as well as the relationship between them. Please validate Sunshine Biopharma variance and potential upside to decide if Sunshine Biopharma is priced more or less accurately, providing market reflects its prevalent price of 0.234 per share. As Sunshine Biopharma appears to be a penny stock we also recommend to double-check its total risk alpha numbers.Sunshine Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sunshine Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sunshine Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sunshine Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Di Turi Michele over a month ago Disposition of tradable shares by Di Turi Michele of Sunshine Biopharma subject to Rule 16b-3 | ||
Steve Slilaty over a month ago Disposition of 1200000 shares by Steve Slilaty of Sunshine Biopharma at 0.02 subject to Rule 16b-3 | ||
Camille Sebaaly over three months ago Acquisition by Camille Sebaaly of 30000 shares of Sunshine Biopharma at 0.7635 subject to Rule 16b-3 | ||
Steve Slilaty over six months ago Acquisition by Steve Slilaty of 1100000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 | ||
Steve Slilaty over a year ago Acquisition by Steve Slilaty of 321305416 shares of Sunshine Biopharma at 0.0026 subject to Rule 16b-3 |
Understand Sunshine Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Sunshine Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.11 | |||
| Market Risk Adjusted Performance | 1.45 | |||
| Mean Deviation | 19.68 | |||
| Semi Deviation | 16.25 | |||
| Downside Deviation | 22.39 | |||
| Coefficient Of Variation | 843.26 | |||
| Standard Deviation | 38.61 | |||
| Variance | 1490.45 | |||
| Information Ratio | 0.1184 | |||
| Jensen Alpha | 4.58 | |||
| Total Risk Alpha | 4.68 | |||
| Sortino Ratio | 0.2041 | |||
| Treynor Ratio | 1.44 | |||
| Maximum Drawdown | 318.64 | |||
| Value At Risk | (30.30) | |||
| Potential Upside | 50.0 | |||
| Downside Variance | 501.46 | |||
| Semi Variance | 264.02 | |||
| Expected Short fall | (32.82) | |||
| Skewness | 4.8 | |||
| Kurtosis | 31.45 |
| Risk Adjusted Performance | 0.11 | |||
| Market Risk Adjusted Performance | 1.45 | |||
| Mean Deviation | 19.68 | |||
| Semi Deviation | 16.25 | |||
| Downside Deviation | 22.39 | |||
| Coefficient Of Variation | 843.26 | |||
| Standard Deviation | 38.61 | |||
| Variance | 1490.45 | |||
| Information Ratio | 0.1184 | |||
| Jensen Alpha | 4.58 | |||
| Total Risk Alpha | 4.68 | |||
| Sortino Ratio | 0.2041 | |||
| Treynor Ratio | 1.44 | |||
| Maximum Drawdown | 318.64 | |||
| Value At Risk | (30.30) | |||
| Potential Upside | 50.0 | |||
| Downside Variance | 501.46 | |||
| Semi Variance | 264.02 | |||
| Expected Short fall | (32.82) | |||
| Skewness | 4.8 | |||
| Kurtosis | 31.45 |
Consider Sunshine Biopharma's intraday indicators
Sunshine Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sunshine Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 0.23 | |||
| Day Typical Price | 0.23 | |||
| Price Action Indicator | 0.006 | |||
| Period Momentum Indicator | 0.004 | |||
| Relative Strength Index | 48.96 |
Sunshine Stock media impact
Far too much social signal, news, headlines, and media speculation about Sunshine Biopharma that are available to investors today. That information is available publicly through Sunshine media outlets and privately through word of mouth or via Sunshine internal channels. However, regardless of the origin, that massive amount of Sunshine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sunshine Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sunshine Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sunshine Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sunshine Biopharma alpha.
Sunshine Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sunshine Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Sunshine Biopharma Corporate Executives
Elected by the shareholders, the Sunshine Biopharma's board of directors comprises two types of representatives: Sunshine Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sunshine. The board's role is to monitor Sunshine Biopharma's management team and ensure that shareholders' interests are well served. Sunshine Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sunshine Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Camille Sebaaly | CFO Secretary | Profile |
Additional Tools for Sunshine Stock Analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.